FGF21: A Literature Course on What the Published Studies Report

This course walks through what the published literature says about FGF21 (fibroblast growth factor 21): how it has been defined and classified, the signalling mechanism described by reviewers, the outcomes reported study by study, adverse or unwanted effects as published, what pharmacokinetic information exists, and how FGF21 and its engineered analogues are positioned in regulatory terms. Nothing here is a protocol, a recommendation or a claim about what FGF21 does in humans outside the studies described. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or before acting on anything you read about a research compound.

Each module closes with an explicit statement of the limits of the evidence being summarised, because the majority of the verified literature used here is mechanistic work in mice and cells rather than controlled human trials.

Module 1 — What FGF21 is and how it has been studied

Definition and class

Reviews of FGF21 physiology described it as a hormone belonging to the endocrine subfamily of fibroblast growth factors, a group that also includes FGF19 and FGF23 and that circulates rather than acting only locally (Understanding the Physiology of FGF21). A metabolic-messenger review characterised FGF21 as a stress- and nutrient-responsive hormone whose expression is induced under conditions such as fasting and metabolic stress (Metabolic Messengers: FGF21). In biochemical terms FGF21 is a protein hormone rather than a short synthetic peptide; the word "peptide" is often applied loosely to it in non-scientific writing, but the published literature treats it as a secreted protein with a defined receptor complex.

Origin and sites of production

Researchers described the liver as the principal source of circulating FGF21, with additional expression reported in adipose tissue, skeletal muscle and the pancreas depending on the stimulus studied (FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance). The same class of review discussed FGF21 as an integrator of nutrient state across liver, fat and brain (Metabolic Messengers: FGF21). Production is not restricted to healthy tissue: a 2024 cancer study reported that tumour cells themselves secreted FGF21 (Tumor-secreted FGF21 acts as an immune suppressor).

Forms used in research

Two broad forms appear in the literature. The first is native or recombinant FGF21 used in animal and cell experiments. The second is the engineered analogue class — long-acting variants and fusion proteins designed to extend exposure — which a 2020 review surveyed as it moved from bench to clinical testing in metabolic disease (The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic). A 2025 study used a delivery format rather than a plain protein, loading FGF21 into M2 macrophage-derived exosomes (FGF21-loaded M2 macrophage-derived exosomes attenuate sepsis-induced lung injury).

Limits of this module: definitions and tissue-of-origin statements come mostly from narrative reviews, which summarise other people's primary data and may emphasise different sources. The term "FGF21" in a paper may refer to the endogenous hormone, a recombinant protein, or a structurally modified analogue with different properties; these are not interchangeable, and the verified papers here do not provide head-to-head comparisons between forms.

Module 2 — Mechanism as described in the literature

The receptor complex

Reviews consistently described FGF21 as signalling through FGF receptors of the "c" splice class in obligate partnership with the co-receptor β-Klotho, which restricts responsiveness to tissues expressing that co-receptor (Understanding the Physiology of FGF21). That co-receptor requirement was presented as the main explanation for FGF21's tissue selectivity compared with paracrine FGFs (Metabolic Messengers: FGF21).

Metabolic signalling described

A 2022 review described FGF21 as a regulator of glucose and lipid handling and of whole-body energy balance, linking its actions to adipose tissue and central nervous system targets (FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance). The translational review framed these pathways as the rationale for testing analogues in metabolic disease (The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic).

Non-metabolic pathways reported

• Vascular axis: a 2018 mouse study reported that FGF21 acted through the ACE2/angiotensin-(1-7) axis in the setting of angiotensin II-induced hypertension (FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction).
• Cardiac mitochondria: a 2025 study reported improvement of cardiac mitochondrial bioenergetics as the mechanism linked to its protective phenotype in a heart failure with preserved ejection fraction model (FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice).
• Central circuits: a 2022 study reported an amygdalo-striatal circuit through which FGF21 suppressed alcohol consumption (FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit), while a 2023 study reported activation of the noradrenergic nervous system in the context of alcohol intoxication (FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system).
• Autophagy: a 2024 paper reported that FGF21 and autophagy acted coordinately in kidney tissue during ageing and obesity (FGF21 and autophagy coordinately counteract kidney disease progression).
• Immune metabolism: the 2024 cancer study reported that FGF21 rewired cholesterol metabolism in CD8+ T cells, an immunosuppressive mechanism (Tumor-secreted FGF21 acts as an immune suppressor).

Limits of this module: mechanisms were defined in genetically modified mice, isolated cells and pharmacological experiments; a pathway demonstrated in one tissue or disease model does not establish that the same pathway dominates in humans. Several mechanisms reported — central circuits, noradrenergic signalling, ACE2 involvement — were described in single research groups' models and have not been shown, in the verified set, to be replicated across species.

Module 3 — Reported outcomes, study by study

The table below lists what each verified primary study examined and what the authors reported. These are descriptions of experiments, not expected outcomes for any person.

Clinical translation as reviewed

The clinical picture in the verified set comes from a review rather than from trial reports: it surveyed FGF21 analogue development for metabolic disease and framed the field as moving from preclinical proof of concept toward clinical evaluation (The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic). A companion review described the metabolic actions that motivated that development programme (FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance).

Limits of this module: every primary outcome above was measured in animals or cells, in disease-induced models, using experimental delivery methods. None of these papers establish outcomes in healthy humans, and the same molecule appeared protective in some models and harmful in the tumour-immunity setting, which is a caution against reading the literature as uniformly favourable. No numerical dose, duration or magnitude of effect is reproduced here because the verified source list does not supply those figures within its abstract scope.

Module 4 — Fgf21 Side Effects: What Studies Report

The verified literature does not contain a systematic human adverse-event catalogue for FGF21. What it does contain are biological effects that researchers themselves framed as undesirable, and review-level discussion of translational safety.

Immunosuppression in a cancer setting

The most explicit unwanted effect in the verified set was reported in 2024, when the study described FGF21 secreted by tumours suppressing CD8+ T-cell function by rewiring cholesterol metabolism — that is, FGF21 activity coinciding with weakened anti-tumour immunity (Tumor-secreted FGF21 acts as an immune suppressor). Notably, a separate 2025 study reported FGF21 acting through the noradrenergic nervous system to protect mice against influenza infection (FGF21 acting on the noradrenergic nervous system protects against influenza virus infection), so the immune literature points in opposite directions depending on the model and cell type studied.

Translational safety discussion in reviews

The 2020 bench-to-clinic review discussed the obstacles facing FGF21-based therapy, including the pharmacological and safety considerations that shaped analogue design (The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic). Physiology reviews similarly noted that FGF21 exerts actions beyond glucose and lipid handling — including effects outside classic metabolic tissues — which reviewers treated as relevant to any pharmacological use (Understanding the Physiology of FGF21), and a metabolic-messenger review described the breadth of FGF21's physiological reach as a reason for caution in interpretation (Metabolic Messengers: FGF21).

Behavioural and autonomic effects

Effects framed as therapeutic in one context are still central nervous system and autonomic actions: the 2022 study reported suppression of alcohol consumption via a brain circuit (FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit), and the 2023 study reported activation of the noradrenergic nervous system (FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system) — a system that governs arousal, heart rate and blood pressure.

Limits of this module: absence of reported adverse events in a preclinical paper is not evidence of safety; rodent studies are not designed or powered to detect the kinds of events monitored in human trials. The verified set contains no human tolerability data, no long-term exposure data and no information about interactions.

Module 5 — Pharmacokinetics where data exist

Pharmacokinetic detail in the verified set is qualitative. Reviews described native FGF21 as a circulating hormone with unfavourable drug-like properties, which is why the analogue field pursued engineered variants and fusion proteins with extended exposure profiles rather than the native protein (The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic). Physiological reviews described endogenous FGF21 as inducible — rising in response to nutritional and metabolic stress states — so circulating concentrations are a moving target rather than a fixed baseline (Metabolic Messengers: FGF21), and a further review linked induction patterns to fasting and nutrient-sensing pathways (Understanding the Physiology of FGF21).

Delivery route also shaped exposure in at least one experiment: researchers packaged FGF21 into macrophage-derived exosomes rather than administering free protein (FGF21-loaded M2 macrophage-derived exosomes attenuate sepsis-induced lung injury).

Limits of this module: no half-life, bioavailability, clearance or volume-of-distribution figures are quoted here because the verified papers do not supply them within the scope used for this page. Pharmacokinetics of an engineered analogue cannot be assumed to describe native FGF21, and rodent pharmacokinetics do not transfer directly to humans.

Module 6 — Regulatory status, stated factually

• Approved products: the verified literature describes FGF21-based therapy as a development field, with the 2020 review presenting analogues as moving from bench toward clinical testing in metabolic disease rather than as established treatments (The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic). FGF21 itself is not marketed as an approved drug product for consumer use.
• Research-use-only material: recombinant FGF21 supplied for laboratory work is labelled research use only. RUO material is not manufactured, tested or labelled as a medicine, and RUO labelling carries no assurance of sterility, identity or purity for human administration.
• Compounding: in the United States, pharmacy compounding of a biologic or bulk substance depends on that substance being eligible under the relevant statutory pathways; a protein that is not a component of an approved product and is not listed as a permitted bulk drug substance does not become compoundable simply because research literature exists.
• Sport and workplace rules: governing bodies set their own lists independently of drug-approval status, so regulatory status in one domain says nothing about permissibility in another.

Limits of this module, and a disclaimer: regulatory frameworks differ by country and change over time, and the verified scientific papers are not regulatory documents. This section is general information, not legal advice; questions about legality or compounding eligibility belong with a qualified attorney or the relevant regulator.

What the studies did not test

Reading the verified set as a whole, several gaps are explicit:

1. Healthy human use. None of the primary studies administered FGF21 to healthy people; the models were disease-induced rodents, tumour systems and cultured cells (PMID 29706566) (PMID 39955281).
2. Long-term exposure. No verified paper reported multi-year outcomes, and the reviews framed FGF21 therapy as an unfinished translational programme (PMID 32764725).
3. Body composition or performance endpoints in humans. The metabolic reviews described glucose, lipid and energy-balance physiology rather than human performance or aesthetic outcomes (PMID 35413740).
4. Cancer-relevant risk in non-cancer settings. The immunosuppressive action was characterised in a tumour context, and the study did not extend that analysis to non-tumour exposure scenarios (PMID 38309268).
5. Comparisons between forms, routes and delivery systems. Exosomal delivery, native protein and engineered analogues appear in separate papers without head-to-head testing (PMID 40889696).

FGF21 is therefore best described as a well-characterised endocrine hormone with an active, and in places contradictory, preclinical literature. Anyone weighing what that literature means for health decisions should do so with a licensed clinician rather than from summaries alone.

References

• Metabolic Messengers: FGF21 (Nature Metabolism, 2021)
• Understanding the Physiology of FGF21 (Annual Review of Physiology, 2016)
• The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic (Nature Reviews Endocrinology, 2020)
• FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance (Hormone and Metabolic Research, 2022)
• FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice (Cell Metabolism, 2018)
• FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice (Nature Communications, 2025)
• FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit (Cell Metabolism, 2022)
• FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system (Cell Metabolism, 2023)
• FGF21 acting on the noradrenergic nervous system protects against influenza virus infection (PNAS, 2025)
• FGF21 and autophagy coordinately counteract kidney disease progression during aging and obesity (Autophagy, 2024)
• FGF21-loaded M2 macrophage-derived exosomes attenuate sepsis-induced lung injury by regulating M2 macrophage polarization and glycolysis (Life Sciences, 2025)
• Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8(+) T cells (Cell Metabolism, 2024)